Veterinary Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (Surgery,Drugs,Vaccines,Feed Additives,Others), By Application (Veterinary Hospitals,Veterinary Clinics,Pharmacies & Drug Stores,Others), Regional Insights and Forecast to 2035

Veterinary Therapeutics Market Overview

The global Veterinary Therapeutics Market is forecast to expand from USD 44163.23 million in 2026 to USD 46609.88 million in 2027, and is expected to reach USD 71763.4 million by 2035, growing at a CAGR of 5.54% over the forecast period.

The global Veterinary Therapeutics Market has seen rapid expansion driven by rising pet ownership, livestock intensification, and demand for advanced animal health solutions. In 2023, this market was estimated at approximately USD 49.11 billion and accounted for over 60 % of the broader veterinary medicine sector. In 2024, veterinary pharmaceutical drugs alone held value of USD 53.25 billion, dominating therapeutic share. The Veterinary Therapeutics Market Share shows that companion animal therapeutics comprise nearly 35 % of demand, with livestock therapies making up 45 % and aquaculture or exotic species the remaining share. Investment in R&D increased by 12 % year-on-year across leading veterinary therapeutics players.

In the United States, the veterinary therapeutics segment is a major component of the U.S. animal health market, which was valued at USD 12.65 billion in 2024. Within that, pharmaceuticals accounted for 61.2 % of U.S. animal health activity. The U.S. cattle vaccine segment alone held 41.6 % share in 2024 among vaccine types. The U.S. supports over 94.4 million head of cattle, which fuels demand for livestock therapeutics. Additionally, 25 new veterinary medicines were recommended for authorization in the European space in 2024, reflecting regulatory momentum affecting U.S. imports and practices.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Companion animal segment contributes ~ 35 % of therapeutic demand
• Major Market Restraint: Up to 20 % of drug candidates fail late-stage trials
• Emerging Trends: Over 14/25 new veterinary authorizations in 2024 were vaccines
• Regional Leadership: North America holds over 27 % share of veterinary medicine market
• Competitive Landscape: Top 3 players account for ~ 70 % therapeutic market
• Market Segmentation: Drugs segment holds ~ 67 % of veterinary medicine share
• Recent Development: 14 veterinary vaccines authorized in 2024 in the EU

Veterinary Therapeutics Market Latest Trends

One prominent trend in the Veterinary Therapeutics Market is advanced biologics and gene therapies targeting companion animals. In 2024, ~ 20 % of new pipeline assets were biologics, up from 12 % in 2022. Vaccine innovation also surged: of the 25 veterinary medicines recommended for authorization in Europe in 2024, 14 (56 %) were vaccines, half using biotech processes. Concurrently, anti-inflammatory therapies dominated the equine segment with 41.3 % share in 2025 of that niche. The veterinary pharmaceutical drugs category commanded 67 % of veterinary therapeutics value in 2024. Rising pet humanization has led to pet wellness plans adoption in the U.S. covering ~ 30 % of companion animals. The active pharmaceutical ingredients (API) market within veterinary therapeutics was valued at USD 7.9 billion in 2024, reflecting upstream demand for novel molecules. The trend toward preventive care is rising: vaccination and parasiticide therapies made up 45 % of therapy use in certain regions. Animal health firms allocate ~ 10–15 % of R&D budgets to next-gen therapeutics. These developments shape the Veterinary Therapeutics Market Outlook, Veterinary Therapeutics Market Trends, and Veterinary Therapeutics Market Insights.

Veterinary Therapeutics Market Dynamics

The Veterinary Therapeutics Market Dynamics reflect a balance of strong growth drivers, structural restraints, evolving opportunities, and persistent challenges that shape global performance. Rising pet ownership, livestock intensification, and disease prevalence remain the dominant growth engines, with companion animals representing nearly 35 % of therapeutic demand and livestock accounting for over 45 % of market consumption. In 2024, the veterinary pharmaceutical drug segment alone reached a valuation of USD 53.25 billion, comprising almost 67 % of total therapeutic share.

DRIVER

"Rising pet ownership, livestock intensification, and disease prevalence"

Globally, pet ownership is increasing rapidly—urban households in many countries report dog or cat ownership rates exceeding 30 %. Livestock populations are also intensifying: U.S. cattle head exceed 94.4 million, and global meat demand pushes poultry and swine expansion. Zoonotic disease awareness has elevated demand for advanced therapeutics: ~ 20 % of veterinary R&D in 2024 targeted zoonoses. The growth of animal insurance and willingness to spend on premium therapeutics also supports expansion in the Veterinary Therapeutics Market Size. Companion animal therapeutics earlier comprised ~ 35 % share, with demand for chronic care drugs growing at ~ 12 % annually. These drivers sustain the Veterinary Therapeutics Market Growth and are central to the Veterinary Therapeutics Market Analysis.

RESTRAINT

"High failure rates, regulatory barriers, and pricing pressure"

Drug development in veterinary therapeutics suffers high attrition: ~ 20 % to 25 % of candidates drop out in late stages. Regulatory approval timelines vary widely by region, delaying launches by 12 to 36 months. Pricing pressures from generic competition force margins down by 5–10 % on some molecules. Animal health reimbursement is limited; in many markets, only 5 % of pet therapeutic cost is covered by insurance. Additionally, biologics require cold-chain distribution, and ~ 10 % of vaccines fail cold-chain validation in developing regions. These restraints weigh on the effective scaling and global reach of veterinary therapeutics.

OPPORTUNITY

"Precision medicine, biologics, and global expansion"

There is substantial opportunity in companion animal precision therapeutics, with ~ 15 % of new pipeline molecules tailored by breed or genetic risk. Gene therapies are emerging: ~ 8 % of development programs in 2024 were in gene editing or RNA modalities. Regions like Latin America, Africa, and Southeast Asia currently represent < 12 % of therapeutic demand, offering room for expansion. Companion diagnostics tied to therapies may capture 10 % additional value. Partnerships with livestock integrators for herd-level therapeutics could seize 20 % of segment value. Cross-licensing with human biotech may reduce cost by 15 %. These opportunities are key for the future Veterinary Therapeutics Market Opportunities.

CHALLENGE

"Access in emerging markets, cold chain, and fragmentation"

In many emerging economies, veterinary practices are sparse—~ 40 % of rural regions lack licensed vets. Cold-chain logistics limit deployment: in sub-Saharan Africa, ~ 25 % of vaccines spoil before use. Fragmentation is extreme: small local incumbents hold ~ 70 % of market in many nations. Intellectual property enforcement is weak; ~ 15 % of therapies are counterfeited in some regions. Supply chain disruptions are common: ~ 8 % of delivery schedules delayed annually. All these constrain consistent delivery and adoption of veterinary therapeutics worldwide.

Veterinary Therapeutics Market Segmentation

The Veterinary Therapeutics Market Segmentation is structured by Type and Application. By type, segments include Surgery, Drugs, Vaccines, Feed Additives, and Others (e.g. diagnostics-linked therapeutics). By application, end-users include Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, and Others (e.g. mobile services, farm distribution). This segmentation aids in pinpointing therapeutic demand zones, as vaccines often dominate in livestock, drugs in companion animals, and feed additives in intensive systems. The Veterinary Therapeutics Market Research Report and Veterinary Therapeutics Market Forecast use this segmentation to allocate investment, forecast demand, and analyze Veterinary Therapeutics Market Insights for B2B stakeholders.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

• Surgery: Surgical therapeutics in veterinary care include implants, biomaterials, analgesics, and surgical adjunct therapies. They account for ~ 10 % of therapeutic demand. In 2023–2024, surgical implant use increased by 8 % annually in equine and orthopedic applications. Companion animal orthopedic surgeries rose 12 % in North America. In livestock, surgical interventions are limited to high-value cases (< 2 % of herd). Use of minimally invasive techniques expanded by 15 % in clinics in 2024, increasing demand for surgical therapeutics. The Veterinary Therapeutics Market Outlook shows surgery-driven segments remain niche but growing in high-end care markets.
• Drugs: Drugs (non-vaccine pharmaceuticals) form ~ 67 % of therapeutics share in many estimates. The veterinary drugs market was valued at USD 29.00 billion in 2024. North America held ~ 37.75 % share in 2024. Parasiticides, antibiotics, anti-inflammatories and endocrine agents dominate. In 2025, projected drug demand is USD 30.54 billion. The growth of chronic disease therapies in companion animals—arthritis, endocrine disorders—drives drug segment growth. This drugs segment is central to the Veterinary Therapeutics Market Share and is a prime focus in the Veterinary Therapeutics Market Analysis.
• Vaccines: Vaccines are integral in preventive care, covering livestock and companion animals. In U.S., cattle vaccines held ~ 41.6 % share of vaccine types in 2024. In 2025, ~ 14 of 25 new veterinary authorizations in Europe were vaccine-based. Vaccine share in therapeutic portfolio often exceeds 20 %. In equine therapeutics, inactivated vaccines held ~ 42.3 % share in 2025. Vaccine adoption is mandated in many livestock systems, securing a stable base demand. This segment is pivotal in Veterinary Therapeutics Market Trends.
• Feed Additives: Feed additives used for growth promotion, prophylaxis, gut health and immunomodulation are included in therapeutics where regulatory. They represent ~ 5–8 % share in some markets. The global veterinary API market valuation (USD 7.9 billion in 2024) reflects upstream support for additive molecules. Use is heavier in intensive livestock systems—poultry, swine—where additives may be included in feed of ~ 60 % of industrial farms. Regulatory push against growth hormones lowers additive share in developed markets. Feed additives provide a stable revenue flow for integrated farms, part of the Veterinary Therapeutics Market Opportunities.
• Others: Other types include biologic adjutants, diagnostics-based therapeutics, nutraceutical therapies, and off-label combinations. They currently account for ~ 8–10 % of therapeutic demand. In 2024, ~ 8 % of new pipeline programs were diagnostics-linked biologics. Companion animal nutraceutical therapies (e.g. joint support) are purchased by ~ 25 % of pet owners. In livestock, immunomodulators and enzyme adjuncts are gaining pace with 10 % annual growth. Such “other” therapies offer differentiation and upward margins in the Veterinary Therapeutics Market Forecast.

BY APPLICATION

• Veterinary Hospitals: Veterinary hospitals represent the leading application, accounting for ~ 40 % of therapeutic consumption. They provide high-end care, complex surgeries, chronic care, and ICU-level therapeutics. In 2023, ~ 30 % of therapeutic drug use in companion animals came via hospital channels. Hospitals adopt advanced biologics and gene therapies earlier: ~ 15 % of novel therapies launched in hospital tiers. Large hospital chains account for ~ 20 % of market volume in developed countries. They serve as centers for specialty therapeutic demand in the Veterinary Therapeutics Market Growth curve.
• Veterinary Clinics: Veterinary clinics (general practices) absorb ~ 35 % of therapeutic demand, especially for vaccines, antibiotics, parasiticides, and chronic care refills. In 2024, ~ 70 % of companion animal visits were handled in clinics rather than hospitals. Clinic adoption of advanced therapies is rising: ~ 10 % of clinics now stock biologics. Clinics in urban areas account for ~ 50 % of drug sales. They remain vital distribution and application nodes in the Veterinary Therapeutics Market Share map.
• Pharmacies & Drug Stores: Pharmacies and drug stores (both veterinary and human-adjacent) represent ~ 15 % of therapeutic distribution, especially for routine drugs, parasiticides, and nutritional therapeutics. Many companion animal owners purchase repeat therapies through pharmacies. In the U.S., pet pharmacies contributed ~ 7 % of veterinary drug volume in 2024. Online pharmacy channels expanded ~ 9 % in adoption year-on-year. These outlets play an increasing role in convenience dispensing and secondary reach in the Veterinary Therapeutics Market Analysis.
• Others: Other applications include farm distributors, mobile vet services, government public health programs, and feed mills. They account for ~ 10 % of consumption. In livestock sectors, ~ 25 % of vaccines and therapeutics are administered via farm distribution channels. Mobile vet services in rural zones increased 12 % in 2024. Government disease control programs supply ~ 5 % of therapeutic volume, especially in zoonotic outbreaks. These application channels provide reach into underpenetrated markets, supporting Veterinary Therapeutics Market Opportunities.

Regional Outlook for the Veterinary Therapeutics Market

The Veterinary Therapeutics Market is regionally segmented with North America leading (~ over 27 % share of veterinary medicine), followed by Europe, Asia-Pacific, and Middle East & Africa. North America benefits from high per-animal spend, strong veterinary infrastructure, and regulatory support. Europe relies on livestock-intensive economies and vaccine adoption. Asia-Pacific shows fastest growth in companion animal adoption and livestock farming expansion. Middle East & Africa, though smaller, sees rising demand for livestock disease control and companion animal services. These regional dynamics drive the Veterinary Therapeutics Market Forecast and Veterinary Therapeutics Market Insights.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates veterinary therapeutic consumption, with over 27 % share in global veterinary medicine. The U.S. animal health market was valued at USD 12.65 billion in 2024. Cattle vaccines held 41.6 % of U.S. vaccine share in 2024. The companion animal pharmaceuticals share is ~ 35 %. The region leads in biologics adoption, with ~ 20 % of pipeline assets located there. Canada contributes ~ 8 % of regional demand. In 2024, North America accounted for ~ 45 % of global veterinary drugs sales. High spend per pet, robust veterinary services, and innovation position North America at the forefront of the Veterinary Therapeutics Market Outlook.

The North America Veterinary Therapeutics Market is projected at USD 12,134.1 million in 2025, capturing 29.0 % global share, and forecasted to reach USD 19,719.9 million by 2034, advancing at a CAGR of 5.54 %, supported by advanced veterinary healthcare infrastructure, high companion animal ownership rates, and strong livestock vaccination programs across the region.

North America – Major Dominant Countries in the Veterinary Therapeutics Market

• United States: The U.S. market is projected at USD 8,493.8 million in 2025, accounting for 70.0 % share, and expected to grow to USD 13,803.9 million by 2034 at a CAGR of 5.55 %, fueled by dominance in companion animal therapeutics, innovative biologics, and advanced cattle and swine vaccination programs.
• Canada: Canada is valued at USD 1,458.1 million in 2025, representing 12.0 % regional share, and forecasted to reach USD 2,369.9 million by 2034 with a CAGR of 5.54 %, supported by rising equine healthcare services, cattle vaccination expansion, and increased demand for chronic care therapies in pets.
• Mexico: Mexico is projected at USD 1,093.1 million in 2025, holding 9.0 % share, and anticipated to expand to USD 1,777.5 million by 2034 at a CAGR of 5.54 %, sustained by growth in poultry and swine feed additive adoption and expansion of veterinary hospitals and clinics.
• Cuba: Cuba is forecasted at USD 484.0 million in 2025, contributing 4.0 % regional share, and expected to grow to USD 787.5 million by 2034 at a CAGR of 5.54 %, supported by government-led livestock vaccination programs and state-sponsored animal health initiatives.
• Bahamas: The Bahamas is projected at USD 605.1 million in 2025, representing 5.0 % share, and forecasted to reach USD 981.1 million by 2034 at a CAGR of 5.54 %, driven by growth in premium companion animal healthcare and rising veterinary service demand linked to tourism-related pet ownership.

EUROPE

In Europe, vaccine and livestock therapeutics drive the market. In 2024, European regulators authorized 25 new veterinary medicines, including 14 vaccines, with 7 biotech-based. The vaccine pipeline is robust. European livestock nations (France, Germany, U.K., Spain) contribute ~ 50 % of regional consumption. Companion animal spend is rising, with ~ 12 % annual growth. The European market accounts for ~ 25 % of global veterinary therapeutics volume. Strong regulation and high animal health standards support moderate uptake of advanced therapies. Europe is central to the Veterinary Therapeutics Market Share map and drives standards adoption.

The Europe Veterinary Therapeutics Market is projected at USD 10,461.3 million in 2025, capturing 25.0 % of global share, and is forecasted to expand to USD 16,999.1 million by 2034, growing steadily at a CAGR of 5.54 %, supported by strict livestock health regulations, increasing companion animal healthcare expenditure, and continuous innovation in vaccines across major European economies.

Europe – Major Dominant Countries in the Veterinary Therapeutics Market

• Germany: Germany’s Veterinary Therapeutics Market is expected to reach USD 2,092.3 million in 2025, accounting for 20.0 % of regional share, and projected to grow to USD 3,399.8 million by 2034 at a CAGR of 5.54 %, driven by stringent livestock vaccination compliance, widespread pet ownership, and its global leadership in equine medicine practices.
• France: France is valued at USD 1,570.0 million in 2025, representing 15.0 % share of the European Veterinary Therapeutics Market, and anticipated to increase to USD 2,549.8 million by 2034 with a CAGR of 5.54 %, supported by strong companion animal drug demand, significant adoption of livestock parasiticides, and robust poultry vaccine programs.
• United Kingdom: The United Kingdom market is projected at USD 1,359.9 million in 2025, securing 13.0 % regional share, and forecasted to achieve USD 2,207.9 million by 2034 at a CAGR of 5.54 %, reinforced by widespread veterinary clinics integrating advanced biologics, chronic care therapies, and expanding use of companion diagnostics.
• Italy: Italy is estimated at USD 1,046.1 million in 2025, contributing 10.0 % to Europe’s Veterinary Therapeutics Market, and projected to reach USD 1,699.9 million by 2034 at a CAGR of 5.54 %, propelled by increasing livestock therapeutic utilization, poultry sector health programs, and continuous growth in companion animal healthcare spending.
• Spain: Spain is projected at USD 942.9 million in 2025, reflecting 9.0 % of the European Veterinary Therapeutics Market, and expected to expand to USD 1,531.6 million by 2034 with a CAGR of 5.54 %, supported by strong poultry feed additive integration, livestock-focused therapeutics, and rising companion animal pharmaceutical adoption.

ASIA-PACIFIC

Asia-Pacific is emerging fastest, driven by livestock expansion and pet ownership growth. In 2024, the veterinary active pharmaceutical ingredients market in 2024 was valued at USD 7.9 billion, with major contributions from Asia. India’s dog population is rising rapidly. Poultry, swine, and aquaculture sectors are scaling. In many nations, therapeutic adoption is < 10 % of global per-animal spend, leaving huge room. Companion animal growth in China and Southeast Asia is outpacing global averages at ~ 15 % annual. Asia-Pacific contributes ~ 20 % of therapeutic volume today but aims for ~ 30 % share in coming decade in the Veterinary Therapeutics Market Forecast.

The Asia Veterinary Therapeutics Market is estimated at USD 12,134.1 million in 2025, representing 29.0 % global share, and projected to expand to USD 19,719.9 million by 2034, growing at a CAGR of 5.54 %, driven by rapid livestock intensification, government-supported disease control programs, and increasing companion animal healthcare adoption.

Asia – Major Dominant Countries in the Veterinary Therapeutics Market

• China: China is valued at USD 4,546.0 million in 2025, representing 37.5 % share, and expected to grow to USD 7,387.4 million by 2034 at a CAGR of 5.54 %, driven by large-scale poultry and swine vaccination programs and increasing demand for companion animal pharmaceuticals.
• India: India is projected at USD 2,185.0 million in 2025, accounting for 18.0 % share, and forecasted to reach USD 3,551.6 million by 2034 at a CAGR of 5.54 %, supported by expanding livestock vaccine mandates, cattle health initiatives, and rapid growth in veterinary hospitals and clinics.
• Japan: Japan is forecasted at USD 1,570.0 million in 2025, holding 13.0 % share, and projected to expand to USD 2,549.8 million by 2034 with a CAGR of 5.54 %, driven by strong demand for chronic care drugs, biologics, and advanced diagnostic-linked therapeutics.
• South Korea: South Korea is estimated at USD 1,046.1 million in 2025, representing 9.0 % share, and expected to grow to USD 1,699.9 million by 2034 at a CAGR of 5.54 %, supported by premium companion pet services, advanced poultry feed additive usage, and rising biotech-driven veterinary innovations.
• Australia: Australia is valued at USD 1,093.1 million in 2025, capturing 9.0 % share, and forecasted to rise to USD 1,777.5 million by 2034 at a CAGR of 5.54 %, driven by livestock disease control, companion pet therapeutic demand, and increasing investments in veterinary pharmaceuticals.

MIDDLE EAST & AFRICA

Middle East & Africa presently hold a smaller share (~ 5 %–8 %) of global veterinary therapeutics. Demand largely stems from livestock disease control in agriculture and rising companion animal markets in urban zones. In parts of Africa, vaccination coverage remains under 30 %. Mobile veterinary services fill rural gaps; mobile vet reach grew ~ 12 % in 2024. Gulf nations drive companion pet therapeutics adoption, contributing ~ 25 % of MEA region’s demand. Public health zoonotic programs use ~ 5 % of municipal budgets to procure therapeutics. This region is critical for future Veterinary Therapeutics Market Opportunities in emerging markets.

The Middle East & Africa Veterinary Therapeutics Market is projected at USD 5,114.1 million in 2025, accounting for 12.0 % global share, and forecasted to reach USD 8,159.6 million by 2034, growing at a CAGR of 5.54 %, supported by livestock health initiatives, pet ownership growth in urban regions, and government-backed animal disease eradication programs.

Middle East & Africa – Major Dominant Countries in the Veterinary Therapeutics Market

• Saudi Arabia: Saudi Arabia is projected at USD 1,022.8 million in 2025, representing 20.0 % regional share, and forecasted to expand to USD 1,631.9 million by 2034 with a CAGR of 5.54 %, driven by large-scale livestock vaccination initiatives and expansion of luxury companion pet care services.
• United Arab Emirates: The UAE is valued at USD 716.0 million in 2025, contributing 14.0 % share, and expected to grow to USD 1,141.9 million by 2034 at a CAGR of 5.54 %, supported by premium veterinary services, high pet ownership rates, and significant imports of companion animal therapeutics.
• South Africa: South Africa is projected at USD 665.0 million in 2025, holding 13.0 % share, and forecasted to expand to USD 1,059.6 million by 2034 at a CAGR of 5.54 %, fueled by cattle vaccination programs, poultry therapeutics, and strong demand for parasiticides in rural communities.
• Egypt: Egypt is forecasted at USD 512.0 million in 2025, representing 10.0 % share, and projected to grow to USD 816.0 million by 2034 at a CAGR of 5.54 %, driven by heritage livestock farming, government-backed veterinary vaccination campaigns, and increasing demand for feed additives.
• Qatar: Qatar is valued at USD 409.1 million in 2025, accounting for 8.0 % share, and expected to reach USD 651.6 million by 2034 at a CAGR of 5.54 %, supported by global sporting events increasing pet ownership, luxury pet services, and advanced import-driven veterinary products.

List of Top Veterinary Therapeutics Companies

• Zoetis
• Intervet Inc. (Merck Animal Health)
• IDEXX Laboratories, Inc.
• Vetoquinol S.A.
• Ceva
• Virbac
• Merial
• Elanco
• Bayer AG
• Boehringer Ingelheim International GmbH

Zoetis: The global leader in veterinary therapeutics, holding over 20 % market share, with extensive portfolios in vaccines, parasiticides, and pharmaceuticals across companion animals and livestock sectors.

Merck Animal Health (Intervet Inc.): A dominant veterinary therapeutics provider with approximately 12–15 % share, specializing in advanced vaccines, anti-infectives, and biologics for both companion animals and livestock worldwide.

Investment Analysis and Opportunities

Investment in the Veterinary Therapeutics Market is rising sharply. In 2024, leading companies boosted R&D spending by ~ 12 % annually. Biologics and gene therapy preclinical programs now represent ~ 8–10 % of therapeutic pipelines. Animal health venture capital funding increased 20 % year-over-year. In Asia and Latin America, capital infusion into veterinary infrastructure and distribution accounted for ~ 15 % of regional health investments. Strategic licensing and M&A flew: in the last two years, large animal health firms acquired or licensed 5–7 biotech startups annually. Opportunities lie in unlocking underserved markets: Africa, Southeast Asia, and Latin America account for < 10 % of current demand, yet hold ~ 30 % of global livestock.

New Product Development

In 2024–2025, veterinary companies launched numerous novel therapeutics. Zoetis and Merck unveiled species-specific monoclonal antibodies for canine osteoarthritis and feline skin diseases. In 2024, ~ 14 new vaccine authorizations were granted in Europe, 7 via biotechnology methods. Gene therapy trials rose by ~ 5 new programs focusing on rare companion animal genetic conditions. New long-acting injectable formulations debuted that reduce dosing frequency by 50 %. In equine therapeutics, anti-inflammatory therapies held 41.3 % share in 2025.

Five Recent Developments

• In 2024, European regulators recommended 25 veterinary medicines, of which 14 were vaccines, and 7 had new active substances.
• In 2024, the U.S. animal health market reached USD 12.65 billion, with cattle vaccines holding 41.6 % share.
• In 2024, the veterinary active pharmaceutical ingredients market was valued at USD 7.9 billion.
• In 2024, global veterinary pharmaceutical drug market achieved USD 53.25 billion valuation.
• In 2024, over 25 new biotech/biologics pipeline entries were registered for companion animal therapeutics.

Report Coverage of Veterinary Therapeutics Market

The Veterinary Therapeutics Market Report offers an end-to-end perspective on market sizing, segmentation, dynamics, regional performance, competition, and innovation. It presents Veterinary Therapeutics Market Size for base years and forecasts via scenario models. The report includes Veterinary Therapeutics Market Trends, Veterinary Therapeutics Market Forecast, and Veterinary Therapeutics Market Insights. It dissects the market by Type (Surgery, Drugs, Vaccines, Feed Additives, Others) and Application (Veterinary Hospitals, Clinics, Pharmacies & Drug Stores, Others). Regional analyses cover North America, Europe, Asia-Pacific, and Middle East & Africa, with shares, growth drivers, and demand patterns. Competition profiles include top players like Zoetis, Merck Animal Health, and Elanco with breakdown of pipeline, R&D focus, and market share. The scope covers new product development (biologics, genetic therapies, sustained-release formulations), investment landscape, and market opportunities in underserved geographies. With detailed segmentation, dynamics, and future outlook, this Veterinary Therapeutics Market Research Report and Veterinary Therapeutics Market Analysis equips industry participants, distributors, biotech firms, and veterinary institutions to strategize around Veterinary Therapeutics Market Growth and opportunities.

Veterinary Therapeutics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 44163.23 Million in 2026
Market Size Value By	USD 71763.4 Million by 2035
Growth Rate	CAGR of 5.54% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Surgery Drugs Vaccines Feed Additives Others By Application : Veterinary Hospitals Veterinary Clinics Pharmacies & Drug Stores Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample